argenx SE Share Price

Equities

ARGX

NL0010832176

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles 16:39:38 24/06/2024 BST 5-day change 1st Jan Change
405.5 EUR +9.06% Intraday chart for argenx SE +12.36% +18.05%

Financials

Sales 2024 * 1.73B 1.85B 146B Sales 2025 * 2.36B 2.54B 200B Capitalization 24.1B 25.87B 2,040B
Net income 2024 * -153M -164M -12.95B Net income 2025 * 197M 211M 16.67B EV / Sales 2024 * 12.6 x
Net cash position 2024 * 2.38B 2.55B 201B Net cash position 2025 * 2.58B 2.77B 218B EV / Sales 2025 * 9.11 x
P/E ratio 2024 *
-166 x
P/E ratio 2025 *
121 x
Employees 1,148
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.88%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on argenx SE

1 day+9.06%
1 week+12.36%
Current month+19.02%
1 month+20.86%
3 months+9.56%
6 months+20.36%
Current year+18.05%
More quotes
1 week
348.20
Extreme 348.2
412.20
1 month
330.90
Extreme 330.9
412.20
Current year
322.50
Extreme 322.5
412.20
1 year
271.00
Extreme 271
494.10
3 years
224.10
Extreme 224.1
494.10
5 years
93.05
Extreme 93.05
494.10
10 years
6.23
Extreme 6.23
494.10
More quotes
Managers TitleAgeSince
Founder 52 31/12/07
Director of Finance/CFO 54 31/05/21
Chief Tech/Sci/R&D Officer - 31/12/14
Members of the board TitleAgeSince
Director/Board Member 71 25/04/17
Director/Board Member 74 12/05/15
Director/Board Member 63 27/04/16
More insiders
Date Price Change Volume
24/06/24 405.5 +9.06% 234,406
21/06/24 371.8 +3.65% 286,132
20/06/24 358.7 +1.44% 53,032
19/06/24 353.6 -0.65% 21,034
18/06/24 355.9 +0.08% 49,281

Real-time Euronext Bruxelles, June 24, 2024 at 04:39 pm

More quotes
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune diseases, and cusatuzumab in hematological cancers in collaboration with Janssen. argenx SE is also advancing several earlier stage experimental medicines within its therapeutic franchises. argenx SE has offices in Belgium, the United States, and Japan.
Calendar
16/07/2024 - R&D Day
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
371.8 EUR
Average target price
449.3 EUR
Spread / Average Target
+20.84%
Consensus